20
2019-09
InxMed Receives US FDA IND Approval to Initiate Clinical Trial for IN10018
Shanghai, China—InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), announced that the Company has obtained FDA (Food and Drug Administration) IND clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor. This is InxMed's first IND opening approved by FDA, which reflects the company's superior R&D capability.
29
2019-07
Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"
20
2019-06
In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE